QS Investors’s Theravance Biopharma TBPH Stock Holding History

QS Investors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,500	Closed	-$57K	–	1674
2019 Q1	$57K	Hold	2,500	–	–	﹤0.01%	1487
2018 Q4	$64K	Hold	2,500	–	–	﹤0.01%	1425
2018 Q3	$82K	Hold	2,500	–	–	﹤0.01%	1427
2018 Q2	$57K	Hold	2,500	–	–	﹤0.01%	1497
2018 Q1	$61K	Hold	2,500	–	–	﹤0.01%	1453
2017 Q4	$70K	Hold	2,500	–	–	﹤0.01%	1429
2017 Q3	$86K	Hold	2,500	–	–	﹤0.01%	1429
2017 Q2	$100K	Buy	+2,500	New	+$96.1K	﹤0.01%	1391

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

QS Investors's TBPH Position: Q2 2019 in Review

QS Investors sold out of Theravance Biopharma (TBPH) in Q2 2019, closing a stake of 2,500 shares — an estimated $57K sold.

QS Investors first reported a position in TBPH in Q2 2017 and held it in 8 quarters. The position peaked at $100K in Q2 2017. 98 funds tracked by Wall St. Rank hold TBPH as of Q2 2019.

QS Investors reported no remaining Theravance Biopharma position as of Q2 2019 after selling out during the quarter.
QS Investors sold 2,500 Theravance Biopharma shares in Q2 2019, an estimated $57K.
QS Investors first reported a position in Theravance Biopharma in Q2 2017 and held it in 8 quarters.
QS Investors's Theravance Biopharma position peaked at $100K in Q2 2017.
98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2019.

Based on QS Investors's 13F filing for Q2 2019, filed 14 Aug 2019.